26 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
30 Jun 23
Regulation FD Disclosure
8:28am
and healthcare platform companies. The company provides drug discovery support, as well as a contract development and manufacturing business (CDMO business), for mRNA medicines and vaccines. (https://corp.arcalis.co.jp/en)
#####
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
28 Apr 23
Regulation FD Disclosure
6:00am
., which owns a group of world-class drug-discovery and healthcare platform companies. The company provides drug discovery support, as well
DEFR14A
g9jw8rvk4c6iohb04k
12 May 22
Revised proxy
5:00pm
8-K
EX-99.1
vzr5m4p
20 Apr 22
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
5:24pm
8-K
EX-1.1
wgx15b
8 Dec 20
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
9:01am
8-K
EX-1.1
gxklil7 i06yl25y3pa
29 Jul 20
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
6:02am
8-K
EX-1.1
2twud3l1
17 Apr 20
Entry into a Material Definitive Agreement
6:06am
10-K
2mycyhs nqfixudrdu4b
16 Mar 20
Annual report
11:09am
8-K
EX-99.1
d0gf45i
4 Mar 20
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR TechnologyTM
8:52am
DEF 14A
nk1kte 13a9
1 Oct 19
Definitive proxy
6:07am